Evidence map›Paper›PMID 42399915›Full record

ArticleJournal of nanobiotechnology2026

Nanoplatforms for EGFR-TKI resistance reversion and immunoactivation in NSCLC by ER stress and siRNA intervention.

Yingshan Qu, Yuping Jiang, Zhenzhen Zhu, Yi Dai, Wenqiao Wang, Zhaohui Li, Lina Ma, Yingming Sun, Danping Liu, Yan Ma and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yingshan QuInstitute of Regenerative Medicine and Laboratory TecKhnology Innovation, Qingdao University, Qingdao, 266071, China.
Yuping JiangKey Laboratory of Marine Drugs, School of Medicine and Pharmacy, Ministry of Education, Ocean University of China, Qingdao, 266003, China.
Zhenzhen ZhuInstitute of Regenerative Medicine and Laboratory TecKhnology Innovation, Qingdao University, Qingdao, 266071, China.
Yi DaiInstitute of Regenerative Medicine and Laboratory TecKhnology Innovation, Qingdao University, Qingdao, 266071, China.
Wenqiao WangDepartment of Spine Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266700, China.
Zhaohui LiDepartment of Spine Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266700, China.
Lina MaPhysical Examination Center, The Affiliated Hospital of Qingdao University, Qingdao, 266700, China.
Yingming SunQingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266071, China.
Danping LiuQingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266071, China.
Yan MaUniversity of Health and Rehabilitation Sciences, Qingdao Municipal Hospital, Qingdao, 266071, PR China.
Wei HanQingdao Key Lab of Common Diseases, Department of Emergency medicine, University of Health and Rehabilitation Sciences, Qingdao municipal Hospital, Qingdao, 266700, China.
Wenhua XuInstitute of Regenerative Medicine and Laboratory TecKhnology Innovation, Qingdao University, Qingdao, 266071, China.
Jinsheng ShiUniversity of Health and Rehabilitation Sciences, Qingdao Municipal Hospital, Qingdao, 266071, PR China.
Xiaoying KongInstitute of Regenerative Medicine and Laboratory TecKhnology Innovation, Qingdao University, Qingdao, 266071, China. kongxiaoying@qdu.ed.cn.

Funding

Horizontal Major Projects in Shandong Province RH2200000157Key Projects of Qingdao Science and Technology Department 20-3-4-43-nshMajor Projects of Shandong Provincial Department of Science and Technology ZR2020ZD11National Key R&D Plan of the Ministry of Science and Technology 2022YFE0132500National Natural Science Foundation of China Grant No. 32571540Natural Science Foundation of Shandong Province Grant No. ZR2022MH187Project of Marine Pilot Laboratory of Ministry of Science and Technology 10-02Special Research Start-up Fund for Distinguished Professors of Qingdao University Grant No. DC2500001103
6 · The paper itself

Abstract

backgroundEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are considered as classic targeted drugs for EGFR-mutated non-small cell lung cancer (NSCLC), but induce EGFR-TKI-resistance and immunosuppression at advanced stage. The targeted inhibition of YES-associated proteins (YAP) combined with immunomodulation is expected to be a distinctive supplementary approach for EGFR-TKI-resistant NSCLC therapy.

methodsHerein an endoplasmic reticulum (ER)-targeting Zn/Cu-bi-single-atom nanoplatform (Zn/Cu-BSRGT) was prepared for EGFR-TKI resistance reversion, cascaded ER stress and immunoactivation. Specifically, after precisely targeting to the ER, Zn/Cu-BSRGT NPs provided simultaneous release of ·OH and

resultsFurthermore, significant glucose consumption and ER stress triggered the immunogenic cell death (ICD) and systemic immune activation, and down-regulated the PERK-Nrf2 signaling pathway and multidrug resistance protein (MRP1).

conclusionIn summary, the combined application of single-atom-nanozyme catalytic technology and gene-targeted silencing technology successfully reversed EGFR-TKI resistance and promoted immunoactivation in NSCLC under ER-targeting assistance, providing support for the new strategic development of drug-resistant NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmEndoplasmic Reticulum StressLung NeoplasmsNanoparticlesProtein Kinase InhibitorsRNA, Small InterferingCell Line, TumorCopperErbB ReceptorsHumansYAP-Signaling ProteinsZincCopperEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsRNA, Small InterferingYAP-Signaling ProteinsZincEGFR-mutated non-small cell lung cancerEGFR-TKI resistanceROS amplificationSiRNA interventionZn/Cu-bi-single-atom nanoplatform

Identifiers

PMID42399915
PMCPMC13602784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.